Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CASP1 | P29466 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 10/20 | 0.67 |
| ▸ | DRD2 | P14416 | 10/20 | 0.67 |
| ▸ | HTR7 | P34969 | 10/20 | 0.67 |
| ▸ | DRD3 | P35462 | 10/20 | 0.67 |
| ▸ | HTR2B | P41595 | 10/20 | 0.67 |
| ▸ | HTR2A | P28223 | 9/20 | 0.67 |
| ▸ | HRH1 | P35367 | 8/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7651660 | 0.91 | ALDH1A1 (0.57) | KDM4EALDH1A1CASP1HTR1ADRD2 | |
| SCHEMBL30230022 | 0.82 | ACKR3 (0.67) | KDM4EALDH1A1CASP1DRD2DRD3 | |
| SCHEMBL28992911 | 0.82 | ACKR3 (0.67) | KDM4EALDH1A1CASP1DRD2DRD3 | |
| SCHEMBL13562512 | 0.81 | KMT2A (0.67) | KDM4EALDH1A1HTR1AHRH1MEN1 | |
| SCHEMBL20358752 | 0.80 | HTR1A (1.00) | KDM4EHTR1ADRD2HTR7DRD3 | |
| SCHEMBL9120363 | 0.80 | KMT2A (0.83) | ALDH1A1HTR1AMEN1KMT2AHDAC1 | |
| SCHEMBL7653036 | 0.79 | HTR1A (0.73) | KDM4EALDH1A1HTR1ADRD2HTR7 | |
| SCHEMBL9121163 | 0.79 | KMT2A (0.81) | ALDH1A1HTR1AMEN1KMT2AHDAC1 | |
| SCHEMBL7647706 | 0.79 | HTR1A (0.81) | KDM4EALDH1A1HTR1ADRD2HTR7 | |
| SCHEMBL4229925 | 0.78 | HTR7 (0.73) | KDM4EHTR1ADRD2HTR7DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010041714-A1 | 5-HT7 receptor antagonists | CAIN GARY A (US) | 2001-11-15 | — | — | US | claimed |
| US-6239143-B1 | TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. | DUPONT PHARMACEUTICALS COMPANY | 2001-05-29 | — | — | US | claimed |
| US-6486173-B2 | SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-11-26 | — | — | US | disclosed |
| US-20010041714-A1 | 5-HT7 receptor antagonists | CAIN GARY A (US) | 2001-11-15 | — | — | US | disclosed |
| US-6239143-B1 | TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. | DUPONT PHARMACEUTICALS COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2000000472-A1 | 5-HT7 RECEPTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041714-A1 | 5-HT7 receptor antagonists | HTR7, HTR5A, HTR1A | KDM4E 3671/4885ALDH1A1 2592/4885CASP1 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.